Discover a complete solution to protect and improve revenue integrity in the face of many new codes, challenges, and trends
®/HCPCS codes for chemistry testing, microbiology, and molecular pathology. More than 100 new PLA codes. New RAC and payer audit targets. Downward-trending payments. All of these changes and trends, along with several others, make 2020 a high-risk year for clinical laboratories. But you can reduce the threats to your compliance and revenue by tapping into the expertise and clear, steady guidance of Robin Zweifel in this annual webcast.
Robin packs a lot of valuable how-to information into 90 minutes: in-depth interpretation, insights, and instruction pertaining to 2020 coding, payment and policy changes, as well as guidance through some of the most challenging areas for laboratories, such as date-of-service rules, drug-of-abuse testing, miscellaneous send-outs for genetic analysis and documentation issues. In short, it’s never been more important to make certain you’re coding and billing compliantly, and we’ll help you get there by breaking down the challenges through clear, practical instruction.
Overcome your obstacles. Don’t let outdated or incomplete information sabotage your compliance. Join the numerous professionals across the country that have embraced our resource for a full range of laboratory solutions.
- Guidance through all the 2020 coding changes, including new CPT/HCPCS codes for chemistry testing, microbiology, and molecular pathology, as well as discussion of new Proprietary Laboratory Analyses (PLA) codes
- Payment changes for 2020, encompassing both the Clinical Laboratory Fee Schedule (CLFS) and Outpatient Prospective Payment System (OPPS), and their impact on laboratories
- Special help with areas of concern, confusion, noncompliance and missed revenue opportunities, including:
- The compliance risks of stacking codes for lab panels of stacking Tier 1 / Tier 2 codes for genetic analysis panels
- New clarification for when it is not appropriate to append modifier 59 for genetic analysis
- How PLA codes should be used, and the risks involved when PLA codes intersect with Category I CPT codes
- Drug-of-abuse testing, including clarification of test methods that do and do not qualify as definitive analysis
- Date-of-service (DOS) rules applicable to diagnostic lab tests and how to satisfy Medicare requirements
- Strategies for protecting the revenue integrity in the face of many threats
- Discussion of the Protecting Access to Medicare Act (PAMA), including the definition of “applicable laboratory”
- Review of NCCI coding guidelines for drug-of-abuse testing, chemistry, hematology, urinalysis, immunology, microbiology, and molecular pathology
- Recovery audit contractor (RAC) targets, including the use of add-on codes when a primary code is missing or denied
- Detailed instruction for detecting and fixing documentation weaknesses that can lead to payment denials; includes the critical difference between “medical necessity” and “medically indicated”
- Time permitting, answers to attendee questions
CPT® is a registered trademark of the American Medical Association.